Zobrazeno 1 - 10
of 16 761
pro vyhledávání: '"S Grover"'
Autor:
IRB Media
Get the Summary of Tim S. Grover with Shari Lesser Wenk's Relentless in 20 minutes. Please note: This is a summary & not the original book. Original book introduction: Relentless: From Good to Great to Unstoppable (2013) by Tim S. Grover, co-written
Autor:
Natalie S. Grover, Kaitlin Annunzio, Marcus Watkins, Pallawi Torka, Reem Karmali, Andrea Anampa-Guzmán, Timothy S. Oh, Heather Reves, Montreh Tavakkoli, Emily Hansinger, Beth Christian, Colin Thomas, Stefan K. Barta, Praveen Ramakrishnan Geethakumari, Nancy L. Bartlett, Geoffrey Shouse, Adam J. Olszewski, Narendranath Epperla
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-7 (2024)
Abstract Marginal zone lymphoma (MZL) can have varied presentations and pathologic features, including high Ki-67 expression ( > 20%) as well as increased numbers of large B cells (LC). However, there are limited data available demonstrating the prog
Externí odkaz:
https://doaj.org/article/3bec38bae50949daa1b5c13aad65aef6
Autor:
Roli Tandon, Caroline E. Boeke, Siddharth Sindhwani, Umesh Chawla, Parag Govil, Oriel Fernandes, Yuhui Chan, Pinnaka Venkata Maha Lakshmi, Gagandeep S. Grover
Publikováno v:
Indian Journal of Public Health, Vol 68, Iss 3, Pp 387-395 (2024)
Background: Hepatitis C virus (HCV) antibody prevalence in Punjab, India (0.56%) is higher than the national average (0.32%), but primary drivers of local transmission are unclear. Objectives: The objective of this study was to identify behavioral an
Externí odkaz:
https://doaj.org/article/73f9f0fc526048ddbcdf34bcb129c243
Autor:
Viktoriya Zelikson, Ashwath Gurumurthi, Yazeed Sawalha, Kaitlin Annunzio, Aditi Saha, Ning Dong, David Qualls, Behzad Amoozgar, Brad Kahl, John Baird, Pavan Challa, Scott F Huntington, Jennifer Santos, Steven Bair, Mayur Narkhede, Shuning Li, Zachary Frosch, Carrie Ho, Stephen D Smith, Allison Winter, Daniel Landsburg, Fateeha Furqan, Mehdi Hamadani, Katelin Baird, Jason Romancik, Hanan Alharthy, Jennie Law, Leyla Bojanini, Ranjana Advani, Boyu Hu, Patrick Connor Johnson, Natalie S. Grover, Mwanasha Merril, Jennifer L. Crombie, Nazila Shafagati, Cole Sterling, Loretta J. Nastoupil, Narendranath Epperla, Emily C Ayers
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
Outcomes in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) are poor. Loncastuximab-teserine (Lonca) is an antibody drug conjugate (ADC) which was FDA approved for R/R DLBCL patients who have received at least 2 prior li
Externí odkaz:
https://doaj.org/article/28e5c35c2c204cf6bb7601f5c351589e
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 19, Iss 3 (2023)
ABSTRACTChimeric antigen receptor T cell (CAR-T) therapy is an innovative immunotherapeutic approach that utilizes genetically modified T-cells to eliminate cancer cells using the specificity of a monoclonal antibody (mAb) coupled to the potent cytot
Externí odkaz:
https://doaj.org/article/cd9a0288508945bfbcae1666194a5fb5
Autor:
Narendranath Epperla, Rina Li Welkie, Pallawi Torka, Geoffrey Shouse, Reem Karmali, Lauren Shea, Andrea Anampa-Guzmán, Timothy S. Oh, Heather Reaves, Montreh Tavakkoli, Kathryn Lindsey, Irl Brian Greenwell, Emily Hansinger, Colin Thomas, Sayan Mullick Chowdhury, Kaitlin Annunzio, Beth Christian, Stefan K. Barta, Praveen Ramakrishnan Geethakumari, Nancy L. Bartlett, Alex F. Herrera, Natalie S. Grover, Adam J. Olszewski
Publikováno v:
Journal of Hematology & Oncology, Vol 16, Iss 1, Pp 1-6 (2023)
Abstract Progression of disease within 24 months (POD24) from diagnosis in marginal zone lymphoma (MZL) was shown to portend poor outcomes in prior studies. However, many patients with MZL do not require immediate therapy, and the time from diagnosis
Externí odkaz:
https://doaj.org/article/4835afa60d3d4971aa7119bfb3356cb7
Publikováno v:
Indian Journal of Community Medicine, Vol 48, Iss 3, Pp 407-412 (2023)
Background: India accounted for 6% of global burden of malaria with 95% population residing in malaria endemic areas. However, Punjab is in the malaria elimination phase with annual parasite incidence (API)
Externí odkaz:
https://doaj.org/article/b5c625c21a594c80810f35285a93dcbd
Autor:
Barbara Savoldo, Gianpietro Dotti, Allison M Deal, Jonathan S Serody, Christopher Dittus, Nicholas P Tschernia, Hillary Heiling, Catherine Cheng, Caroline Babinec, Megan Gonzalez, J Kaitlin Morrison, Anne W Beaven, William A Wood, Natalie S Grover
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 8 (2023)
Chimeric antigen receptor (CAR)-T cells targeting CD30 have demonstrated high response rates with durable remissions observed in a subset of patients with relapsed/refractory CD30+ hematologic malignancies, particularly classical Hodgkin lymphoma. Th
Externí odkaz:
https://doaj.org/article/37ff0a870b1541c7ae281d7f0e1e2333
Autor:
Narendranath Epperla, Qiuhong Zhao, Sayan Mullick Chowdhury, Lauren Shea, Tamara K. Moyo, Nishitha Reddy, Julia Sheets, David M. Weiner, Praveen Ramakrishnan Geethakumari, Malathi Kandarpa, Ximena Jordan Bruno, Colin Thomas, Michael C. Churnetski, Andrew Hsu, Luke Zurbriggen, Cherie Tan, Kathryn Lindsey, Joseph Maakaron, Paolo F. Caimi, Pallawi Torka, Celeste Bello, Sabarish Ayyappan, Reem Karmali, Seo-Hyun Kim, Anna Kress, Shalin Kothari, Yazeed Sawalha, Beth Christian, Kevin A. David, Irl Brian Greenwell, Murali Janakiram, Vaishalee P. Kenkre, Adam J. Olszewski, Jonathon B. Cohen, Neil Palmisiano, Elvira Umyarova, Ryan A. Wilcox, Farrukh T. Awan, Juan Pablo Alderuccio, Stefan K. Barta, Natalie S. Grover, Nilanjan Ghosh, Nancy L. Bartlett, Alex F. Herrera, Geoffrey Shouse
Publikováno v:
Journal of Hematology & Oncology, Vol 15, Iss 1, Pp 1-6 (2022)
Abstract Ibrutinib is effective in the treatment of relapsed/refractory (R/R) marginal zone lymphoma (MZL) with an overall response rate (ORR) of 48%. However, factors associated with response (or lack thereof) to ibrutinib in R/R MZL in clinical pra
Externí odkaz:
https://doaj.org/article/742e9377f2884da1b8eeb0b6ff560e57